As per the exchange filing, Biocon Biologics will take responsibility across the product lifecycle, which includes ...

According to PL Capital, Ajanta Pharma's strong franchise will aid in garnering a higher market share for semaglutide ...

The shares of the company closed at Rs 381.60 apiece on Monday, the lowest level seen by the stock in over three weeks.

Ajanta Pharma has signed an in-licensing pact with Biocon to commercialise semaglutide in 26 countries across Africa, the ...

Biocon will fully integrate its biosimilars arm, Biocon Biologics into the parent, in a deal valuing the unit at $5.5 billion. The move is aimed at cr.

Kiran Mazumdar-Shaw-led Biocon Ltd has engaged four investment banks as advisors as the leading global bio-pharmaceutical firm prepares for a fresh capital raise of up to Rs 4,500 crore ( $500 mn), ...

The inspection was conducted by the US FDA between October 6-10, 2025, under current Good Manufacturing Practice (cGMP) ...

Biocon Biologics has gained complete global rights for Hulio, a biosimilar Adalimumab. This move grants Biocon Biologics full ...

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...

Under the agreement, Biocon will supply semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive ...

Rajesh Palviya of Axis Securities advises buying Biocon with a stop loss at Rs 395 and a target of Rs 414. Out of 18 analysts tracking the company, 11 maintain a 'buy' rating, two recommend a 'hold,' ...